Metabolic syndrome in patients with prostate cancer undergoing androgen suppression

Moróte, Juan; Ropero, J.; Planas, Jacques; Celma, Ana; Placer, J.; Ferrer, Roser; Torres, Inés de

doi:10.1016/j.acuroe.2014.03.002

Cited by 3 publications

(9 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, the last four studies were excluded for failing to provide a control group. Eight studies were finally included in the present study (Figure ). Table S1 showed the excluded reasons of full‐text articles.…”

Section: Resultsmentioning

confidence: 99%

“…Eight studies involving 157,588 participants were identified to investigate the relationship between ADT and diabetes. Among 65,695 ADT users, 7,136 patients (approximately 10.9%) developed diabetes compared with 6,987 events (approximately 7.6%) in 91,893 non‐ADT users (RR 1.39; 95% CI 1.27–1.53; P < 0.001; Figure a), indicating that ADT is strongly associated with an increased risk of diabetes morbidity.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Androgen deprivation therapy is associated with diabetes: Evidence from meta‐analysis

Wang

Sun

Zhao

et al. 2016

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/IntroductionThere is still no obvious evidence proving that androgen deprivation therapy (ADT) would increase the risk of diabetes. To determine if ADT is associated with diabetes in men with prostate cancer, we carried out the present study.Materials and MethodsWe systematically searched Medline, Embase and the Cochrane Library Central Register through 2014. Studies comparing ADT vs control aimed at treating prostate cancer reporting diabetes as outcome were included. Data were extracted independently by two reviewers. This meta‐analysis was reported based on the Preferred Reporting Items for Systematic reviews and Meta‐Analyses checklist. Observational studies were evaluated through the Meta‐analysis Of Observational Studies in Epidemiology checklist.ResultsEight studies were identified with 65,695 ADT users and 91,893 non‐ADT users. The pooled incidence of diabetes was 39% higher in ADT groups. A significant association was observed in the overall analysis (risk ratio [RR] 1.39, 95% confidence interval [CI] 1.27–1.53; P < 0.001). In subgroup analyses, diabetes was found to be significantly associated with gonadotropin‐releasing hormone (GnRH) alone (RR 1.45, 95% CI 1.36–1.54; P < 0.001), GnRH plus oral antiandrogen (RR 1.40, 95% CI 1.01–1.93; P = 0.04) and orchiectomy (RR 1.34, 95% CI 1.20–1.50; P < 0.001), but not with antiandrogen alone (RR 1.33, 95% CI 0.75–2.36; P = 0.33). Diabetes was strongly related to long duration of ADT (RR 1.43, 95% CI 1.22–1.68; P < 0.001), and was slightly associated with short duration of ADT (RR 1.29, 95% CI 1.12–1.49; P = 0.0004).Conclusions ADT, especially long duration (>6 months) of this treatment, GnRH alone, GnRH plus antiandrogen and orchiectomy can increase the incidence of diabetes.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Androgen deprivation therapy is associated with diabetes: Evidence from meta‐analysis

Wang

Sun

Zhao

et al. 2016

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…11,12,13 In one of those studies, Braga-Basaria et al 12 reported a MetS prevalence of 20% in the control group vs. 22% in PCa patients without ADT and 55% in patients who underwent ADT. A more recent study by Cleffi et al 13 compared two groups of PCa pts: in one group, pts received a mean of 15 months of ADT while the other group did not undergo ADT, reporting a significant difference in MetS prevalence (54% vs. 24%, respectively).…”

Section: Discussionmentioning

confidence: 99%

“…A more recent study by Cleffi et al 13 compared two groups of PCa pts: in one group, pts received a mean of 15 months of ADT while the other group did not undergo ADT, reporting a significant difference in MetS prevalence (54% vs. 24%, respectively). The most recently published crosssectional study was conducted by Morote et al 11 who found a MetS prevalence of 32% in a control group (no PCa) vs. 36% in PCa patients without ADT treatment, and 51% in patients who received ADT. Relevant to our study, those authors observed that MetS prevalence increased progressively over time in the ADT group (44% vs. 57%, respectively, with <3 vs. >3 years of ADT).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study

Ots

García

Kavadoy

et al. 2015

Reports of Practical Oncology & Radiotherapy

View full text Add to dashboard Cite

show abstract

Optimizing screening and management of cardiovascular health in prostate cancer

Kenk

Grégoire

Côté

et al. 2020

CUAJ

View full text Add to dashboard Cite

In clinical practice, cancer management does not consistently encompass screening and identification of cardiovascular (CV) risk. The use of androgen deprivation therapy (ADT) in prostate cancer has been associated with increased CV risk and development of metabolic syndrome, necessitating identification of patients at risk in this population (e.g., those with pre-existing CV disease). A multi-disciplinary team of Canadian physicians was assembled to develop a series of recommendations intended to identify patients who may benefit from optimal management of their cardiovascular disease and/or modification of cardiac risk factors. A key goal was the development of a simple screening tool for identification of patients with pre-existing CV disease. This simple and inclusive set of recommendations are intended for use within urology clinics to facilitate holistic approaches and simplify the management of patients.

show abstract

Metabolic syndrome in patients with prostate cancer undergoing androgen suppression

Cited by 3 publications

References 22 publications

Androgen deprivation therapy is associated with diabetes: Evidence from meta‐analysis

Androgen deprivation therapy is associated with diabetes: Evidence from meta‐analysis

SIMBOSPROST: Prevalence of metabolic syndrome and osteoporosis in prostate cancer patients treated with radiotherapy and androgen deprivation therapy: A multicentre, cross-sectional study

Optimizing screening and management of cardiovascular health in prostate cancer

Contact Info

Product

Resources

About